the announcement that volpara has singed an agreement to distribute ScreenPoint's Transpara product looks quite positive.

Volpara state that combining Volpara and Transpara can reduce radiologist liability and risk as well as cutting screening costs. So it appears that there is a good reason to be sell them combined.

Fro Shareholders if the revenue per user can be increased that is a great outcome and higher recurring revenue expectatons going forward.

I have always felt that the ARPU seemed low and that over time it would need to increase for Volpara to become a really great investment. hopefully this is another step in the right direction.

https://www.asx.com.au/asxpdf/20190708/pdf/446g5vdsz2ths5.pdf